• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

唾液标本在监测人类免疫缺陷病毒感染患者茚地那韦治疗中的应用。

Use of saliva specimens for monitoring indinavir therapy in human immunodeficiency virus-infected patients.

作者信息

Wintergerst U, Kurowski M, Rolinski B, Müller M, Wolf E, Jaeger H, Belohradsky B H

机构信息

Department of Infectious Diseases and Immunology, Federal Republic of Germany.

出版信息

Antimicrob Agents Chemother. 2000 Sep;44(9):2572-4. doi: 10.1128/AAC.44.9.2572-2574.2000.

DOI:10.1128/AAC.44.9.2572-2574.2000
PMID:10952622
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC90112/
Abstract

Indinavir concentrations were determined in plasma and saliva over a random period of 4 h. On average, levels in saliva were 70% +/- 38% of the corresponding levels in plasma. These findings suggest that saliva might serve as an appropriate specimen for monitoring of plasma indinavir levels in patients treated with indinavir.

摘要

在4小时的随机时间段内测定了血浆和唾液中的茚地那韦浓度。平均而言，唾液中的浓度为血浆中相应浓度的70%±38%。这些发现表明，唾液可能是监测接受茚地那韦治疗患者血浆茚地那韦水平的合适标本。

相似文献

1
Use of saliva specimens for monitoring indinavir therapy in human immunodeficiency virus-infected patients.唾液标本在监测人类免疫缺陷病毒感染患者茚地那韦治疗中的应用。
Antimicrob Agents Chemother. 2000 Sep;44(9):2572-4. doi: 10.1128/AAC.44.9.2572-2574.2000.
2
Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals.初治HIV-1感染个体中奈非那韦和茚地那韦的治疗药物监测
AIDS. 2003 May 23;17(8):1157-65. doi: 10.1097/00002030-200305230-00007.
3
Therapeutic drug monitoring of indinavir and nelfinavir to assess adherence to therapy in human immunodeficiency virus-infected children.茚地那韦和奈非那韦的治疗药物监测，以评估人类免疫缺陷病毒感染儿童的治疗依从性。
Pediatr Infect Dis J. 2002 Aug;21(8):743-7. doi: 10.1097/00006454-200208000-00009.
4
Saliva as a specimen for monitoring compliance but not for predicting plasma concentrations in patients with HIV treated with indinavir.唾液作为监测接受茚地那韦治疗的HIV患者依从性的标本，但不能用于预测其血浆浓度。
Ther Drug Monit. 2000 Aug;22(4):437-45. doi: 10.1097/00007691-200008000-00013.
5
Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV-infected patients.根据HIV感染患者的病毒学反应确定茚地那韦和奈非那韦的血浆谷浓度疗效阈值。
HIV Med. 2004 Jul;5(4):307-13. doi: 10.1111/j.1468-1293.2004.00226.x.
6
Therapeutic drug monitoring of indinavir in HIV-infected patients undergoing HAART.接受高效抗逆转录病毒治疗的HIV感染患者中茚地那韦的治疗药物监测。
Infection. 2002 Jan;30(1):13-6. doi: 10.1007/s15010-001-1111-0.
7
Protease inhibitor drug levels in the management of human immunodeficiency virus-1 antiretroviral therapy.蛋白酶抑制剂药物水平在人类免疫缺陷病毒1型抗逆转录病毒治疗管理中的作用
Int J STD AIDS. 2003 Feb;14(2):103-8. doi: 10.1258/095646203321156863.
8
Indinavir plasma concentration and adherence score are codeterminant of early virologic response in HIV-infected patients of the APROCO cohort.茚地那韦血药浓度和依从性评分是APROCO队列中HIV感染患者早期病毒学反应的共同决定因素。
Ther Drug Monit. 2005 Feb;27(1):63-70. doi: 10.1097/00007691-200502000-00013.
9
Alterations in serum levels of lipids and lipoproteins with indinavir therapy for human immunodeficiency virus-infected patients.茚地那韦治疗人类免疫缺陷病毒感染患者时血清脂质和脂蛋白水平的变化。
Clin Infect Dis. 1999 Aug;29(2):441-3. doi: 10.1086/520231.
10
Indinavir-based treatment of HIV-1 infected patients: efficacy in the central nervous system.
AIDS. 1999 Jul 9;13(10):1227-32. doi: 10.1097/00002030-199907090-00012.

引用本文的文献

1
Antiretroviral bioanalysis methods of tissues and body biofluids.组织和生物体液的抗逆转录病毒生物分析方法。
Bioanalysis. 2013 Feb;5(3):351-68. doi: 10.4155/bio.12.319.
2
Supporting children to adhere to anti-retroviral therapy in urban Malawi: multi method insights.支持马拉维城市地区儿童坚持抗逆转录病毒治疗：多方法见解
BMC Pediatr. 2009 Jul 14;9:45. doi: 10.1186/1471-2431-9-45.

本文引用的文献

1
Indinavir concentrations and antiviral effect.茚地那韦浓度与抗病毒作用。
Pharmacotherapy. 1999 Jun;19(6):708-12. doi: 10.1592/phco.19.9.708.31544.
2
Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study.人类免疫缺陷病毒1型蛋白酶抑制剂相关脂肪代谢障碍、高脂血症和糖尿病的诊断、预测及自然病程：一项队列研究
Lancet. 1999 Jun 19;353(9170):2093-9. doi: 10.1016/S0140-6736(98)08468-2.
3
Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1.
J Infect Dis. 1999 May;179(5):1116-23. doi: 10.1086/314703.
4
Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up.茚地那韦、齐多夫定和拉米夫定联合或序贯治疗HIV-1感染：100周随访
JAMA. 1998 Jul 1;280(1):35-41. doi: 10.1001/jama.280.1.35.
5
Single-dose pharmacokinetics of indinavir and the effect of food.茚地那韦的单剂量药代动力学及食物的影响。
Antimicrob Agents Chemother. 1998 Feb;42(2):332-8. doi: 10.1128/AAC.42.2.332.
6
A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.一项针对人类免疫缺陷病毒感染且每立方毫米CD4细胞计数为200或更低的患者，使用两种核苷类似物加茚地那韦的对照试验。艾滋病临床试验组320研究团队。
N Engl J Med. 1997 Sep 11;337(11):725-33. doi: 10.1056/NEJM199709113371101.
7
A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir).HIV蛋白酶抑制剂MK-639（茚地那韦）的一项为期24周的开放标签I/II期评估。
AIDS. 1996 May;10(5):485-92. doi: 10.1097/00002030-199605000-00006.
8
Monitoring theophylline therapy using citric acid-stimulated saliva in infants and children with asthma.
Pediatrics. 1987 Dec;80(6):894-7.
9
Statistical methods for assessing agreement between two methods of clinical measurement.评估两种临床测量方法之间一致性的统计方法。
Lancet. 1986 Feb 8;1(8476):307-10.
10
Evaluation of saliva as a specimen for monitoring zidovudine therapy in HIV-infected patients.评估唾液作为监测HIV感染患者齐多夫定治疗的标本。
AIDS. 1991 Jul;5(7):885-8. doi: 10.1097/00002030-199107000-00015.